Osiris Pays $1.5M Penalty, Settles SEC Charges over Accounting Practices

Osiris Therapeutics has agreed to pay a $1.5 million civil penalty and settle charges by the U.S. Securities and Exchange Commission (SEC) that the company, its ex-CEO, and three other former executives engaged in unlawful accounting practices that misled investors.Without admitting or denying the SEC allegations, Osiris said it will consent to a final judgment, subject to court approval, that includes the penalty and permanently restrains and enjoins the company from violating federal securitie